semaglutide and chronic kidney disease in patients with overweight or obesity without diabetes: a randomized double-blind placebo-controlled clinical trial Patients with type 2 #diabetes

According to the financial reports by Novo Nordisk, the business revenue of GLP-1 RAs has reached 34,653 million Danish krone (DKK) in the first quarter of 2023 ( The FDA Adverse Event Reporting System (FAERS) is a robust pharmacovigilance database that contains real-world data on AE reporting ( Methods Data sources FAERS is an openly accessible pharmacovigilance database documenting AEs, medication errors, and product quality complaints reported spontaneously by people of diverse occupations worldwide ( Data extraction In order to acquire AE reports data treated with GLP-1 RAs, we identified the AEs of GLP-1 RAs in the DRUG files using the generic and brand names of the FDA-approved GLP-1 RAs, specifically exenatide (BYETTA, BYDUREON), liraglutide (VICTOZA, SAXENDA), lixisenatide (ADLYXIN, SOLIQUA), dulaglutide (TRULICITY), semaglutide (OZEMPIC, RYBELSUS, WEGOVY), and tirzepatide (MOUNJARO)

When energy fluctuates, running for time is far more sustainable than running for distance. Time-based training: A time-based program is ideal for people on GLP-1s because it adapts to your daily energy

Appetite suppression becomes noticeable here

Mounjaro vs Zepbound often sparks discussions because both utilize the active ingredient tirzepatide

Chiricosta L, Gugliandolo A, Mazzon E